FDA Calendar

PDUFA dates and FDA Panel Review dates are very important because they are make or break events for biostocks when the decisions are announced. Also, usually biostocks experience a run-up going into the scheduled decision/review dates. So having prior knowledge of the catalysts goes a long way toward maximizing profit or minimizing loss while trading volatile biotech stocks.

Listed below are large cap, mid cap and small cap stocks with pending regulatory catalysts.

Get in-depth analysis and insight on investing in the high-stakes biotech and pharma sectors. Check out our
premium biotech research product and our biotech home page.
Company Name
Adamis Pharmaceuticals Corp
Symjepi (sNDA)
FDA decision on low dose Symjepi (0.15mg) for the emergency treatment of anaphylaxis
Akcea Therapeutics Inc.
Volanesorsen (NDA)
FDA decision on Volanesorsen for the treatment of familial chylomicronemia syndrome (FCS).
Tetraphase Pharmaceuticals
Eravacycline (NDA)
FDA decision on Eravacycline for the treatment of complicated intra-abdominal infections
Mallinckrodt plc
Stannsoporfin (NDA)
FDA decision on Stannsoporfin for treatment of neonates at risk for developing severe hyperbilirubinemia, or severe jaundice
Alnylam Pharmaceuticals Inc.
Patisiran (NDA)
FDA decision on Patisiran for the treatment of hereditary ATTR (hATTR) amyloidosis
Akcea Therapeutics Inc.
FDA decision on Inotersen for hereditary TTR amyloidosis (hATTR)
Dermira Inc.
Glycopyrronium tosylate (NDA)
FDA decision on Glycopyrronium tosylate for primary axillary hyperhidrosis
GW Pharmaceuticals PLC
Epidiolex (NDA)
FDA decision on Epidiolex for treatment of seizures associated with Lennox-Gastaut syndrome and Dravet syndrome
Achaogen Inc.
Plazomicin (NDA)
FDA decision on Plazomicin for the treatment of complicated urinary tract infections, and bloodstream infections
scPharmaceuticals Inc.
Furoscix (505(b)(2) NDA)
FDA decision on Furoscix for treatment of worsening, or decompensated, heart failure outside of the inpatient setting
Teva Pharmaceutical Industries Limited
Fremanezumab (BLA)
FDA decision on Fremanezumab for the treatment of migraine
Recro Pharma Inc.
IV Meloxicam (NDA)
FDA decision on IV Meloxicam for the management of moderate to severe pain
Dova Pharmaceuticals, Inc.
Avatrombopag (NDA)
FDA decision on Avatrombopag for the treatment of thrombocytopenia in patients with chronic liver disease
Amgen Inc.
Aimovig (BLA)
FDA decision on Aimovig for the prevention of migraine
Valeant Pharmaceuticals International
FDA decision on PLENVU for cleansing of the colon in preparation of colonoscopy
pharma-031518.jpg Another week has rolled by, and as usual, the biotech sector saw some stocks soaring to the moon and some hitting the skids. Let's take a look at the pharma stocks and upcoming events to keep an ear out for in the coming week.
Pharma-031418.jpg Today's Daily Dose brings you news about Arcus' IPO; Catalyst Pharma's near-term catalysts; FDA clinical hold on Solid Biosciences' IGNITE DMD study, and clinical trial events of Proteostasis that are worth keeping an eye on.
Pharma-031218.jpg Today's Daily Dose brings you news about the clinical hold on Advaxis' HPV-associated cancers trial; encouraging pre-clinical trial results of Altimmune's investigational SparVax-L against anthrax infection; encouraging interim data from BioSpecifics Technologies' Phase I trial of Collagenase Clostridium Histolyticum for the treatment of uterine fibroids; Breakthrough Therapy Designation for Prote
Read More
Graphene, a form of carbon, which was discovered in 2004, is said to have the potential for use in a variety of applications, say in the fields of electricity, conductivity, energy generation and storage, sensors, batteries, and many more. Now, researchers have identified a new use for this material - making better hair dyes.
A study published by Oxford University Press has found that smokers are at a greater risk of hearing loss. The study involved 50,000 participants, aged 20-64 years, who were followed up for a maximum of 8 years in Nicotine & Tobacco Research.
Read More